The efficacy of fibroblast growth factor for the treatment of chronic vocal fold scarring

The efficacy comparison of fibroblast growth factor versus pre-made human dermal matrix for the treatment of chronic vocal fold scarring or sulcus vocalis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001855

Enrollment

Registered

2016-03-22

Start date

2012-04-05

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Procedure/Surgery : To the recruited patients with chronic vocal fold scar, all of the FGF injection procedures were performed percutaneously under local anesthesia by a single surgeon (SW Lee)

Olympus, Tokyo, Japan). FGF (Fiblast®, Kaken Pharmaceutical Co., Tokyo, Japan), at a dose of 10–15 µg in 0.2–0.3 ml, was injected into Reinke's space. The choice of injection approach – cricothyroid,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Based on the results of a stroboscopic examination, history of chronic vocal fold scarring of over 1 year’s duration

Exclusion criteria

Exclusion criteria: Patients with a history of other vocal fold diseases, such as vocal fold atrophy, vocal fold mucosal lesion, granuloma, or sulcus vocalis, or a history of malignant tumors of the vocal fold were excluded.

Design outcomes

Primary

Measure	Time frame
Voice evaluation (jitter and shimmer,harmonics-to-noise ratio,maximum phonation time,voice range profile, GRBAS(Grade, Roughness, Breathiness, Asthenia, Strain) scale, Voice Handicap Index ,stroboscopy)	—

Secondary

Measure	Time frame
Safety	—

Countries

Korea, Republic of

Contacts

Public ContactMyung Jin Ban

Soon Chun Hyang University Hospital Cheonan

mjbanent@gmail.com

Outcome results